Literature DB >> 6143634

Cardioselectivity, kinetics, hemodynamics, and metabolic effects of xamoterol.

G Jennings, A Bobik, C Oddie, R Restall.   

Abstract

Xamoterol is a new orally active partial beta-adrenoceptor agonist. Its kinetics, hemodynamic and metabolic effects, and cardioselectivity were investigated in eight normal subjects. Plasma xamoterol concentrations after 100 micrograms/kg iv declined biexponentially over 8 hr and t 1/2 beta averaged 2.6 hr. Resting heart rate (HR) increased slightly in the supine position but was unchanged on sitting. Systolic blood pressure (SBP) rose by 5 to 10 mm Hg and cardiac index (CI) rose 15% to 20%. Both parameters were above control values 6 hr after dosing, when plasma xamoterol concentrations had fallen to about 10 ng/ml. There were no changes in diastolic or mean arterial pressure (MAP). During graded exercise the effects of xamoterol on HR and SBP were the reverse of those at rest, with lowering of exercise HR and SBP at higher work loads. CI during exercise was not altered by xamoterol. Doses of xamoterol were calculated from the kinetic data to give plasma concentrations of 100, 200, 400, and 800 ng/ml. HR and blood pressure effects at each xamoterol level were compared before and after inhibition of cardiovascular reflexes with prazosin, atropine, and clonidine. Hemodynamic effects of xamoterol and isoproterenol were compared. Before autonomic block xamoterol increased HR by 10 bpm and MAP by 7 mm Hg at the highest dose. After autonomic block there was a 200% to 300% rise in HR at each dose and MAP still rose. The rise in MAP after block could be entirely accounted for by a 23% increase in CI because total peripheral resistance did not change. The effects of isoproterenol after autonomic block were a rise in HR and a fall in MAP. Metabolic responses to xamoterol were measured at the four dose levels. There was a dose-related increase in nonesterified fatty acids and a fall in plasma lactate levels but no changes in plasma renin activity or blood glucose. Results suggest that xamoterol is a cardioselective partial beta-adrenoceptor agonist in man.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6143634     DOI: 10.1038/clpt.1984.82

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

Review 1.  Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Authors:  D G Waller
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

2.  Pharmacokinetics of xamoterol after intravenous and oral administration to patients with chronic heart failure.

Authors:  E V Sorensen; O Faergeman; M Day; W Bastain
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 3.  Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  R Furlong; R N Brogden
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

4.  Modulation of the autonomic control of the failing heart.

Authors:  H M Snow
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

Review 5.  The pharmacology of xamoterol: a basis for modulation of the autonomic control of the heart.

Authors:  H M Snow
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

6.  Myocardial, coronary, and peripheral effects of xamoterol (ICI 118,587) in open-chest pigs.

Authors:  N Galiè; M Metalli; R Zannoli; G Binetti; A Branzi; B Magnani
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

7.  Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers.

Authors:  W Bastain; M J Boyce; L E Stafford; P B Morton; D A Clarke; H F Marlow
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  Influence of xamoterol, a partial beta 1-selective agonist, on physical performance capacity and cardiocirculatory, metabolic and hormonal parameters.

Authors:  T Kullmer; W Kindermann; A Urhausen; M Hess
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

10.  Comparison of the effects of xamoterol, atenolol and propranolol on breathlessness, fatigue and plasma electrolytes during exercise in healthy volunteers.

Authors:  E V Sørensen; H K Jensen; O Faergeman
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.